Pharma

Your Article Summary

See Latest Articles

Innovation Over Imitation
PharmExec, 10/16/09

With revenue prospects increasingly static for small molecules, the onus is on drugmakers to generate new sources of "spark." Follow–on biologics (FOBs) have been cast as the next big driver of growth, but there are trip wires that could short–circuit any strategies for competing in this segment. While FOBs have tremendous revenue potential, companies must consider a number of risk factors when staking a claim in the business—unique science, regulatory complexities, and the head start granted a few key players suggest that this is not a sector for the faint of heart.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

CCHIT Appoints Officers
HealthDataManagement, 12/18/09

 See all of Research & Development